The Hebrew University of Jerusalem has announced a groundbreaking advancement in diabetes research, as Prof. Yuval Dor and Dr. Agnès Klochendler, distinguished members of the Faculty of Medicine and the Institute for Medical Research Israel-Canada, have been awarded the prestigious European Research Council (ERC) Advanced Grant. This accolade, granted under the European Union’s highly competitive Horizon Europe program, represents one of the most selective funding opportunities designed to empower senior scientists to pursue innovative, high-impact research endeavors with transformative potential.
The ERC Advanced Grant supports projects that push the boundaries of current scientific understanding. In this instance, Prof. Dor and Dr. Klochendler’s grant backs a pioneering investigation into the earliest molecular events that instigate type 1 diabetes (T1D), a chronic autoimmune condition characterized by the immune-mediated destruction of insulin-producing pancreatic beta cells. Their novel approach challenges the conventional paradigm, which attributes disease onset primarily to viral infections as critical immunogenic triggers.
Contrary to long-standing beliefs, their research proposes that intrinsic disruptions in RNA metabolism within the beta cells themselves may serve as the initial catalyst driving autoimmunity. More specifically, the team is focusing on RNA editing—a post-transcriptional modification process that precisely alters nucleotide sequences of RNA molecules, modulating gene expression and maintaining cellular homeostasis. Defects in this sophisticated editing machinery could lead to the production of aberrant proteins, misfolded peptides, or dysregulated signaling pathways that, in turn, precipitate the breakdown of immune tolerance.
The project seeks to elucidate how perturbations in RNA editing mechanisms might generate novel autoantigens or modify immune checkpoint pathways, ultimately triggering misguided immune responses. This mechanistic insight stands to redefine our understanding of beta cell vulnerability and autoimmune initiation in T1D, moving beyond the simplistic infectious trigger hypothesis toward a more intricate cell-intrinsic etiology. By delving into the intricate layers of RNA processing—such as adenosine-to-inosine (A-to-I) editing mediated by the ADAR enzymes—the researchers aim to uncover molecular signatures that precede clinical onset.
Beyond its fundamental scientific contributions, this research holds promise for revolutionary clinical applications. Identifying early biomarkers of disrupted RNA metabolism may enable the development of diagnostic tools capable of detecting T1D risk before overt beta cell destruction occurs. Furthermore, therapeutic strategies designed to restore or modulate RNA editing fidelity could emerge as novel interventions to prevent or attenuate disease progression.
Prof. Dor and Dr. Klochendler’s multidisciplinary approach combines state-of-the-art molecular biology, single-cell transcriptomics, and immunological profiling to meticulously dissect the interplay between beta cell intrinsic defects and immune system dynamics. Their work harnesses cutting-edge sequencing technologies and bioinformatic analyses to characterize RNA editomes and perturbations in patient-derived samples and experimental models.
The significance of this research resonates beyond T1D, as RNA metabolism and editing dysregulation have been implicated in a spectrum of autoimmune and inflammatory diseases. Therefore, unraveling these fundamental processes has the potential to reshape therapeutic strategies across a broad range of immunopathologies. The ERC Advanced Grant thus acknowledges not only the high scientific caliber of the investigators but also the broad societal impact their findings may yield.
Prof. Oron Shagrir, Rector of the Hebrew University of Jerusalem, emphasized the gravity of this achievement, recognizing the awardees’ scientific excellence and visionary research agenda. He highlighted how this project exemplifies the university’s commitment to tackling pressing global health challenges through innovative biomedical science. The university community anticipates that their work will propel the field toward novel modalities of disease interception and enhance quality of life for millions affected by T1D worldwide.
As Prof. Dor and Dr. Klochendler embark on this ambitious research journey, the global scientific community watches eagerly. Their findings promise to expand our grasp of the molecular underpinnings of autoimmunity and illuminate early intervention pathways. The ERC Advanced Grant not only funds the exploration of uncharted scientific territory but also evidences a vital step toward rewriting the narrative of type 1 diabetes pathogenesis.
In summary, this research heralds a paradigm shift by situating RNA editing defects at the heart of autoimmune diabetes initiation. It challenges prevailing dogmas and integrates cutting-edge molecular insights with translational promise. As this project unfolds, it may unlock new vistas in immunology, molecular medicine, and patient care, offering hope to those at risk of or battling type 1 diabetes.
Subject of Research: Early molecular mechanisms underlying type 1 diabetes initiation, with a focus on RNA metabolism and RNA editing dysregulation in pancreatic beta cells.
Article Title: Unveiling RNA Editing Dysregulation as a Novel Trigger of Autoimmune Diabetes: ERC Grant Awarded to Prof. Yuval Dor and Dr. Agnès Klochendler
News Publication Date: Not specified
Web References: Not specified
References: Not specified
Image Credits: Dor Lab
Keywords: Type 1 diabetes, autoimmune disease, RNA metabolism, RNA editing, ERC Advanced Grant, beta cells, pancreatic islets, autoimmune pathogenesis, molecular biology, immunology, ADAR enzymes, Horizon Europe
